TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Paclitaxel, Carboplatin, and Panitumumab in Treating Patients With Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion~* Pathologically confirmed invasive breast cancer with ER \< 10%, PR \< 10%, by IHC, HER2 1+ or 0 or FISH negative~* Measurable (\>= 1 cm) or assessable disease detectable by imagining or physical exam~* Patients with bone only disease have measurable lesions on x-ray, MRI, or CT scan~* Only one or no prior therapy for metastatic or recurrent breast cancer is allowed~* Prior chemotherapy or radiation therapy is permitted but at least 2 weeks should elapse prior to study enrollment~* Prior therapy with bevacizumab is permitted but at least 2 weeks should elapse prior to study enrollment~* Prior therapy with bevacizumab is permitted but at least 28 days should elapse from the last bevacizumab treatment prior to study enrollment~* ECOG PS or 0-1~* Signed protocol specific informed consent prior to registration~* Life expectancy greater than 3 months~* Please contact study investigator and/or consult the protocol document for specific laboratory criteria~* Tissue block available from primary breast cancer~* Premenopausal women must have a negative serum or urine pregnancy test prior to starting on study treatment (post-menopausal is defined as \> 6 months of amenorrhea prior hysterectomy)~Exclusion~* More than or equal to 2 prior regimens for metastatic breast cancer~* Leptomeningeal disease~* Brain metastasis except for a solitary lesion that was resected or treated with gamma knife with no residual disease on CT or MRI or received whole brain RT and f/u MRI was normal with no residual neurologic deficit~* History of interstitial lung disease (ie pneumonitis, pulmonary fibrosis) or evidence of interstitial lung disease on baseline chest computerized tomography (CT) scan~* History of irreversible neuropathy~* Another malignancy other than carcinoma in situ of the cervix or skin cancer~* Active uncontrolled bacterial viral or fungal infection~* Active pregnancy or breast feeding~* Patients with pre-existing neuropathy \>= grade 2~* History of myocardial infarction, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia~* Patients with previous history of CTCAE grade \>= 3 hypersensitivity to paclitaxel or Cremophor EL are not eligible

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): Patients receive paclitaxel IV and carboplatin IV on days 1, 8, and 15. Patients also receive panitumumab IV on days 1 and 15.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Ketorolac Use in Pediatric Patients Undergoing Tonsillectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~-ASA physical status I to III, age of 2 years to 18 years old (inclusive) scheduled for elective tonsillectomy with or without adenoidectomy.~Exclusion Criteria:~-Exclusion criteria are: allergy to any nonsteroidal anti-inflammatory medications, bleeding disorders, history of gastrointestinal bleeding, renal impairment, severe asthma, cardiac/hepatic disease, use of anticoagulation, recent NSAID use (within last 72 hours) or any other medical problem that in the opinion of investigator would interfere with study participation.

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 18 Years
- Healthy Volunteers: t

Study Arms:
- Ketorolac Tromethamine (Type: EXPERIMENTAL): This group receives Ketorolac Tromethamine 0.5 mg/kg IV up to a maximum dose of 30mg, in the form of Ketorolac Tromethamine solution for IV/IM use 30mg/ml single dose vial at the completion of the tonsillectomy in the operating room.
- 0.9% Normal Saline (Type: PLACEBO_COMPARATOR): This group will receive 0.9% Normal Saline solution 1ml/60kg up to 1ml IV bolus (an equivalent volume as per kg Ketorolac Tromethamine dose) at the completion of the tonsillectomy in the operating room.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ocrelizumab in Combination With Methotrexate in Patients With Rheumatoid Arthritis Who Are Naive to Methotrexate (FILM)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Age ≥ 18~* Rheumatoid arthritis for 3 months-5 years~* Naive to methotrexate~* If receiving steroids or NSAIDs, must be on a stable dose for 4 weeks prior to baseline~Exclusion criteria:~* Rheumatic autoimmune disease or inflammatory joint disease other than RA~* Prior receipt of any biologic therapy for RA~* Concurrent treatment with any DMARD

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): Participants received placebo intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, 76, and 78. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
- Ocrelizumab 200 mg (Type: EXPERIMENTAL): Participants received ocrelizumab 200 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54 and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.
- Ocrelizumab 500 mg (Type: EXPERIMENTAL): Participants received ocrelizumab 500 mg intravenously on Days 1 and 15 and Weeks 24, 26, 52, 54, and 76. Participants also received methotrexate 7.5 mg orally weekly starting on Day 1. The dose of methodrexate was increased to a dose of 20 mg per week by Week 8, administered in 1 dose or divided into 3 equal doses administered at 12-hour intervals. Participants also received folate ≥ 5 mg/week either as a single dose or as a divided weekly dose. Participants were also allowed to continue receiving background corticosteroid therapy, at a dose of ≤ 10 mg/day of prednisolone or prednisolone.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Automated Oxygen Titration with O2matic Home Oxygen Therapy (O2matic HOT) Phase 1

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Verified COPD with FEV1/FVC \< 0.70~* Need of LTOT (PaO2 \<= 7.3 kPa or SpO2 \< 88 % on ambient air)~* Cognitively able to participate~* Willing to provide informed consent~Exclusion Criteria:~* Moderate or severe exacerbation in COPD within 4 weeks from study start~* Major comorbidities (cancer, uncontrolled chronic disease)~* Asthma or other disease with need of higher SpO2~* Pregnancy~* Fall in pH below 7.35 or increase in PaCO2 \> 1 kPa on 5 liters of oxygen~* Active smoking~* LTOT use less than 1 hours/day

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Manual (Type: ACTIVE_COMPARATOR): Fixed dose oxygen
- O2matic (Type: EXPERIMENTAL): Automated oxygen titration

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Eumycetoma Long-term Post-Treatment Follow-Up Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Clinical trial participants who were previously enrolled and received investigational product (fosravuconazole) or standard of care treatment (itraconazole) in the DNDi-FOSR-04-MYC clinical trial.~2. In trial DNDi-FOSR-04-MYC had no recurrence of eumycetoma lesion before month 15.~3. Able and willing to give written informed consent for participation in this study, prior to performance of any study procedures.~Exclusion Criteria:~1. Any condition that, in the opinion of the Principal Investigator or designee, would preclude provision of informed consent or interfere with achieving the study objectives.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Nudges to Improve Health Behaviors That Limit COVID-19 Spread

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18 years or older~* Provision of signed and dated informed consent form~* Willingness to comply with all study procedures and lifestyle considerations and availability for the duration of the study~* Has at least 1 risk factor associated with COVID-19 documented in their electronic medical record~* Followed by (i.e., actively receiving care) from targeted MCW specialties (Internal Medicine, OBGYN, Surgery)~* Access to necessary resources for participating in a technology-based activities (i.e., internet access + mobile phone or computer to complete online survey)~* Maintains a personal address where study materials can be shipped and where participant lives full time~Exclusion Criteria:~* Previous COVID-19 diagnosis or positive COVID-19 test result documented in their electronic medical record~* Current participation in another treatment or intervention study associated with COVID-19~* Previous documented Obsessive-Compulsive Disorder diagnosis in their electronic medical record~* Non-English speaker~* Patients hospitalized or incapacitated at onset of potential enrollment~* No access to electronic platform with internet (e.g., smartphone, tablet, computer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Inertia (Type: ACTIVE_COMPARATOR): Participants simply receive and subsequently have default access (i.e., readily and immediately available) to handwashing (HW) materials. This condition will functionally serve as a control comparison. As the term implies, inertia capitalizes on minimizing effort necessary (e.g., going to the grocery store) to engage in HW behavior in one's personal environment.
- Anchoring (Type: EXPERIMENTAL): Involves once again providing default access to HW materials as above, but adds an explicit written cue to wash hands at a rate of (15) times per day, which is placed directly on the soap dispenser. The stimulus is intended to deliberately prime participant thinking (and subsequent behavior) towards a higher reference point that overshoots a desired target rate of 10+ daily HWs.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Is Laparoscopic Fundoplication Better Than Open Fundoplication in Children ?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age 0-15 years~* All patients accepted for primary fundoplication at Oslo University Hospital~Exclusion Criteria:~* Age over 16 years~* Parents not speaking Norwegian or English well~* Prior fundoplication~* Patients with comorbidities considered as unsuited for laparoscopic surgery (diaphragma hernia, several previous abdominal operations etc)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Open fundoplication (Type: ACTIVE_COMPARATOR): Fundoplication performed with open surgery
- Lap fundoplication (Type: EXPERIMENTAL): Primary fundoplication performed by laparoscopic surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Observational Study on Rectal Cancer to Verify if Response After Chemo-radiotherapy Can be Predicted With a Particular Blood Test.

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years old~* Locally advanced rectal cancer (T3 or T4, and/or N+) requiring long course nCRT (as decided by the regional tumor board)~* Patient fit for surgery and treated with curative intent~* Willingness to complete all clinical and radiological examinations foreseen by the study~* Availability of tissue specimen for molecular characterization at baseline~* Written informed consent~Exclusion Criteria:~* Presence of metastases~* Insufficient material on the tissue biopsy to be left in archives of the Cantonal Institute of Pathology for further evaluations/analyses~* Insufficient amount of tumor cells in the tissue biopsy for the molecular characterization~* Inability to consent and follow the procedures of the study~* Women who are pregnant or breast feeding

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Cervical Laminectomy to Laminoplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: All must be met for inclusion in the study.~* The patient must be at least 18 years of age and have no evidence of developmental anomaly of the cranial cervical junction and/or cervical spine~* The patient has the diagnosis of cervical myelopathy~* The myelopathy or myeloradiculopathy requires a posterior cervical decompression of the spinal canal involving two or more contiguous intervertebral levels including and between C3 and C7~* The patient signs the study informed consent form.~Exclusion Criteria:~* Primary symptoms and signs of cervical radiculopathy (only) without myelopathy.~* Presence of primary focal anterior compression of the cervical spinal cord.~* Ossification of the ligamentum flavum.~* Previous surgery of the cervical spine.~* Tumor, infection, or trauma of the cervical spine or cord.~* Segmental instability - Pregnant or interested in becoming pregnant during the study follow-up period.~* Known sensitivity to device materials.~* Currently being treated or intends to be treated postoperatively with other devices for the same disorder (e.g., electrical stimulation devices, pain control devices, etc.).~* Currently a participant in any other study related to the treatment of cervical spinal disorders.~* Prisoner~* Mentally incompetent, or unable to comply with the follow up regime

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Laminectomy (Type: ACTIVE_COMPARATOR): Control
- Laminoplasty (Type: ACTIVE_COMPARATOR): Treatment group

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Compression Headphone Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Adults (18-99 years) with ≥3 months hearing aid experience~* binaural, symmetric, sensorineural N3 to N4 hearing loss~* able to use Android interface and receive a video call on phone/computer~* fluent in English~Exclusion Criteria:~* children/teenagers~* normal hearing or hearing loss exceeding N4 by 10dB~* cannot wear over-ear headphones

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Receiver-in-canal hearing aid 1 default (Type: ACTIVE_COMPARATOR): Receiver-in-canal hearing aid with current default compression strategy
- Receiver-in-canal hearing aid 2 (Type: ACTIVE_COMPARATOR): Receiver-in-canal hearing aid from a different manufacturer with default compression strategy
- Receiver-in-canal hearing aid 1 strategy 1 (Type: EXPERIMENTAL): Receiver-in-canal hearing aid with modified compression strategy 1
- Receiver-in-canal hearing aid 1 strategy 2 (Type: EXPERIMENTAL): Receiver-in-canal hearing aid with modified compression strategy 2
- No device (Type: NO_INTERVENTION): Stimuli recordings without hearing aid

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Oxygen Therapy for Renal Regeneration in Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* The participants are patients of age 18 years or older, who suffered DKD, defined as eGFR\<60ml/min as estimated using MDRD formula, and albuminuria in the presence of diabetes. Diabetic retinopathy and without any alternative cause for their renal disease.~Exclusion Criteria:~* Exclusions criteria are chest pathology incompatible with HBOT, inner ear disease, claustrophobia. Smoking is not allowed during the study. Patients with uncontrolled diabetes HBA1C\>7.5, recent AKI (3M) recent cardiovascular or cerebrovascular event (6M) or inability to hold the breath for 20-30 seconds are also excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- HBOT treatment (Type: OTHER): HBOT treatment: 60 daily sessions, 5 days/week, 120 minutes each, 100% oxygen at 2ATA.
- Standard treatment (Type: NO_INTERVENTION): follow up with the standard recommended treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Noscapine HCl (CB3304 ) in Patients With Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Advanced Multiple Myeloma.~* Progression after ≥ 2 lines of prior therapy, including at least one steroid, one immunomodulatory agent (iMID), one alkylator, and bortezomib (VELCADE®).~* ECOG performance status of either 0 or 1.~Exclusion Criteria:~* Prior chemotherapy with antimicrotubule agents~* Metastasis involving the brain or spinal cord~* Clinically significant lung or heart disease~* Abnormal electrocardiogram~Please note that there are additional inclusion and exclusion criteria. The study center will determine if you meet all of the criteria.~Site personnel will explain the trial in detail and answer any question you may have if you do qualify for the study. You can then decide whether or not you wish to participate. If you do not qualify for the trial, site personnel will explain the reasons.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- One (Type: EXPERIMENTAL): Noscapine HCl

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Implementation and Evaluation of a Social Journey Accompanied in Breast Cancer Diagnosis (EPARS SEIN)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient major\> 18~* Have a diagnosis of localized breast cancer requiring surgery immediately adjuvant therapy sequence including chemotherapy and radiotherapy~* Being more than 3 years of retirement at diagnosis~* Have a work contract valid at the time of diagnosis (before surgery)~* Do not practice a profession~* Be in possession of his rights (excluding guardianship, curatorship)~* Raise the general social security scheme and have rights to cash benefits in the Languedoc-Roussillon region~Exclusion Criteria:~* Patient minor~* Patient diagnosed with metastatic breast cancer~* Patients refusing to sign the consent~* Patients do not have sufficient understanding of the French language~* Patients for whom it is impossible to give clear information

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group intervention (Type: EXPERIMENTAL): Personalized coaching coordinated by a coordinating nurse on a shutdown period of 8 months (consecutive stops).
- Group standard (Type: NO_INTERVENTION): conventional support

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy